Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2018

  • ID: 4461750
  • Drug Pipelines
  • 63 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Shionogi & Co Ltd
  • Theravance Biopharma Inc
  • MORE
Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2018

Summary:

The latest pharmaceutical and Healthcarel and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2018., provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape.

Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes stool to move through the gastric system. They increase non-propulsive contractions in the middle of the small intestine (jejunum) and decrease longitudinal propulsive peristalsis - motions critical to moving food through the intestines. This results in food that fails to travel through the digestive tract. Opioids are also able to partially paralyze the stomach (gastroparesis) so that food remains in the digestive organ for a longer period of time. Additionally opioids reduce digestive secretions and decrease the urge to defecate. Symptoms of OIC include feeling and being sick, tiredness and lethargy, appetite loss, feeling depressed.

Report Highlights:

The latest pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2018., provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 2, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Report Coverageproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opioid-Induced Constipation (OIC) (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opioid-Induced Constipation (OIC) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Shionogi & Co Ltd
  • Theravance Biopharma Inc
  • MORE
Introduction

Report Coverage

Opioid-Induced Constipation (OIC) - Overview

Opioid-Induced Constipation (OIC) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Opioid-Induced Constipation (OIC) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development

Ironwood Pharmaceuticals Inc

Shionogi & Co Ltd

Sucampo Pharmaceuticals Inc

Synergy Pharmaceuticals Inc

Theravance Biopharma Inc

Opioid-Induced Constipation (OIC) - Drug Profiles

(axelopran sulfate + oxycodone hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

axelopran sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dolcanatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linaclotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lubiprostone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methylnaltrexone bromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naldemedine tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride PR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Opioid-Induced Constipation (OIC) - Dormant Projects

Opioid-Induced Constipation (OIC) - Discontinued Products

Opioid-Induced Constipation (OIC) - Product Development Milestones

Featured News & Press Releases

Oct 12, 2017: Shionogi and Purdue Pharma Announce U.S. Availability of Symproic (naldemedine) for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

Sep 06, 2017: Shionogi and Purdue Pharma to Present Data from Naldemedine Studies at PAINWeek 2017 Annual Conference

Jun 07, 2017: Opioid-Induced Constipation therapeutic agent ‘Symproic (naldemedine) Tablets 0.2mg’ launched in Japan

Mar 30, 2017: Symproic (naldemedine) Approved for the Treatment of Opioid-Induced Constipation in Japan

Mar 24, 2017: EMA Accepts MAA Submission of Shionogi’s Naldemedine for the Treatment of Opioid-Induced Constipation

Mar 23, 2017: FDA Approves Symproic (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

Dec 19, 2016: Shionogi and Purdue Pharma Establish Alliance for Joint U.S. Commercialization of Naldemedine

Sep 07, 2016: Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation

Jun 06, 2016: Shionogi Announces Acceptance Of New Drug Application In The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation

May 23, 2016: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation

Mar 30, 2016: Shionogi Submits New Drug Applications In Japan And The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation

Feb 19, 2016: Naldemedine Phase 3 Study Shows Significant Improvement for Patients with Opioid-Induced Constipation

Nov 30, 2015: Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation

Sep 10, 2015: Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination (FDC) of Axelopran (TD-1211) and Oxycodone at PAINWeek 2015

Aug 03, 2015: Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Opioid-Induced Constipation (OIC) - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018

Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co Ltd, H1 2018

Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals Inc, H1 2018

Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals Inc, H1 2018

Opioid-Induced Constipation (OIC) - Pipeline by Theravance Biopharma Inc, H1 2018

Opioid-Induced Constipation (OIC) - Dormant Projects, H1 2018

Opioid-Induced Constipation (OIC) - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Ironwood Pharmaceuticals Inc
  • Shionogi & Co Ltd
  • Sucampo Pharmaceuticals Inc
  • Synergy Pharmaceuticals Inc
  • Theravance Biopharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll